Nasdaq · CIK 0001386570
NAGE Niagen Bioscience, Inc.
Insider trading from SEC Form 4. Last filing Feb 24, 2026. Close $2.69 on Oct 9, 2026, +1% from the 52-week low and -65% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
NAGEOct 9, 2026 · close 2.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Niagen Bioscience, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Ozan Pamir Chief Financial Officer buy | $46k 6,685 shares | +230% | +31% from low-52% from high | |
| 18Weak | Carlos Luis Lopez SVP, General Counsel buy | $2,146 273 shares | +14% | - | |
| 18Weak | Frank L Jaksch Jr director sell | $230k 37,161 shares | -13% | - | |
| 30Weak | Ozan Pamir Chief Financial Officer buy | $21k 2,907 shares | - | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 13, 2024 | Frank Jaksch Jr. affiliate | 37,161 0.05% of outstanding | $230k | Dec 13, 2024 | none |
Transactions
The last 24 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Carlos Luis Lopez SVP, General Counsel | AGrant or award Employee Stock Options (right to buy)derivative | +41,420 | $0.00 | $0 | 41,420 | Feb 24, 2026 |
| Feb 19, 2026 | Ozan Pamir Chief Financial Officer | AGrant or award Employee Stock Options (right to buy)derivative | +62,131 | $0.00 | $0 | 62,131 | Feb 24, 2026 |
| Feb 19, 2026 | Robert N Fried Chief Executive Officer | AGrant or award Employee Stock Options (right to buy)derivative | +503,937 | $0.00 | $0 | 503,937 | Feb 24, 2026 |
| Nov 14, 2025 | Ozan Pamir Chief Financial Officer | POpen-market purchase Common Stock | +4,465 | $6.81 | $30k | 7,372 | Nov 17, 2025 |
| Nov 14, 2025 | Ozan Pamir Chief Financial Officer | POpen-market purchase Common Stockindirect: The reported securities are held by the reporting person's spouse. | +2,220 | $6.85 | $15k | 2,220 | Nov 17, 2025 |
| Jun 24, 2025 | Hamed Shahbazi director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jul 3, 2025 |
| Jun 24, 2025 | Kristin Patrick director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Wing Tak Wendy YU director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Ann Cohen director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 25, 2025 |
| Jun 24, 2025 | Frank L Jaksch Jr director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 25, 2025 |
| Jun 24, 2025 | Wang Yu Gary Ng director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 25, 2025 |
| Jun 24, 2025 | Steven D Rubin director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 25, 2025 |
| Apr 9, 2025 | Robert N Fried Chief Executive Officer | MOption exercise Common Stock | +66,667 | $3.30 | $220k | 1,038,981 | Apr 9, 2025 |
| Apr 9, 2025 | Robert N Fried Chief Executive Officer | MOption exercise Stock Options (right to buy)derivative | -66,667 | $0.00 | $0 | 0 | Apr 9, 2025 |
| Mar 7, 2025 | Carlos Luis Lopez SVP, General Counsel | POpen-market purchase Common Stock | +273 | $7.86 | $2,146 | 2,251 | Mar 10, 2025 |
| Feb 25, 2025 | Robert N Fried Chief Executive Officer | AGrant or award Performance Stock Unitderivative | +1,518,600 | $0.00 | $0 | 1,518,600 | Feb 27, 2025 |
| Feb 12, 2025 | Robert N Fried Chief Executive Officer | AGrant or award Employee Stock Options (right to buy)derivative | +492,278 | $0.00 | $0 | 492,278 | Feb 14, 2025 |
| Feb 12, 2025 | Ozan Pamir Chief Financial Officer | AGrant or award Employee Stock Options (right to buy)derivative | +17,230 | $0.00 | $0 | 17,230 | Feb 14, 2025 |
| Feb 12, 2025 | Carlos Luis Lopez SVP, General Counsel | AGrant or award Employee Stock Options (right to buy)derivative | +19,691 | $0.00 | $0 | 19,691 | Feb 14, 2025 |
| Dec 13, 2024 | Frank L Jaksch Jr director | MOption exercise Common Stock | +50,001 | $3.66 | $183k | 281,340 | Dec 13, 2024 |
| Dec 13, 2024 | Frank L Jaksch Jr director | SOpen-market sale Common Stock | -37,161 | $6.19 | $230k | 244,179 | Dec 13, 2024 |
| Dec 13, 2024 | Frank L Jaksch Jr director | MOption exercise Employee Stock Options (right to buy)derivative | -50,001 | $0.00 | $0 | 0 | Dec 13, 2024 |
| Nov 22, 2024 | Ozan Pamir Chief Financial Officer | POpen-market purchase Common Stock | +2,907 | $7.36 | $21k | 2,907 | Nov 25, 2024 |
| Oct 21, 2024 | Ozan Pamir Chief Financial Officer | AGrant or award Employee Stock Options (right to buy)derivative | +146,544 | $0.00 | $0 | 146,544 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ann Cohendirector
- Robert N FriedChief Executive Officer
- Frank L Jaksch Jrdirector
- Carlos Luis LopezSVP, General Counsel
- Wang Yu Gary Ngdirector
- Ozan PamirChief Financial Officer
- Kristin Patrickdirector
- Steven D Rubindirector, officer
- Hamed Shahbazidirector
- Wing Tak Wendy YUdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.